International Journal of Hematology最新文献_第2页

Peritoneal lymphomatosis with CD5-positive diffuse large B-cell lymphoma. 腹膜淋巴瘤伴cd5阳性弥漫性大b细胞淋巴瘤。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-04-01 Epub Date: 2025-02-18 DOI: 10.1007/s12185-025-03950-0

Satoshi Ichikawa, Shunsuke Hatta, Hideo Harigae

引用次数: 0

Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia. Venetoclax和阿扎胞苷联合高杉碱、阿糖胞苷和阿克鲁比星治疗复发/难治性T细胞急性淋巴细胞白血病。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-04-01 Epub Date: 2025-01-23 DOI: 10.1007/s12185-025-03915-3

Lin-Sen Feng, Hui-Yuan Li, Ai Tang, Meng-Li Xu, San-Bin Wang

{"title":"Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.","authors":"Lin-Sen Feng, Hui-Yuan Li, Ai Tang, Meng-Li Xu, San-Bin Wang","doi":"10.1007/s12185-025-03915-3","DOIUrl":"10.1007/s12185-025-03915-3","url":null,"abstract":"Background: The treatment of relapsed/refractory T cell acute lymphoblastic leukemia (R/R T-ALL) is a significant challenge in hematologic oncology, and no standard salvage treatment plan exists. Both Chinese and international clinical guidelines recommend combination chemotherapy including venetoclax.Methods: Efficacy and safety of venetoclax, azacitidine, homoharringtonine, cytarabine, and aclarubicin (VA-HAA) combination therapy were retrospectively analyzed in 3 patients with R/R T-ALL at the Department of Hematology, 920th Hospital of the Joint Logistics Support Force, Chinese People's Liberation Army.Results: The chemotherapy resulted in CR/CRi with negative flow MRD in all 3 patients. Quantitative negative conversion was achieved in 2 patients with fusion genes, and the frequency of monoclonal TCR gene rearrangements was significantly reduced in 1 patient. All patients received stem cell rescue after the chemotherapy. Hematologic toxicity may be manageable, with a median of 24 days for complete recovery of neutrophils (ANC) and 36 days for partial recovery of platelets. There were no major bleeding events or chemotherapy-related deaths.Conclusion: VA-HAA may be an effective and safe salvage treatment for R/R T-ALL, and prospective clinical trials are needed to verify its specific clinical efficacy.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"547-552"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia. 水合柠檬酸铁治疗缺铁性贫血的成本-效果。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-04-01 Epub Date: 2024-12-26 DOI: 10.1007/s12185-024-03905-x

Mikio Momoeda, Kyoko Ito, Sachie Inoue, Hidetoshi Shibahara, Yuko Mitobe, Norio Komatsu

{"title":"Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia.","authors":"Mikio Momoeda, Kyoko Ito, Sachie Inoue, Hidetoshi Shibahara, Yuko Mitobe, Norio Komatsu","doi":"10.1007/s12185-024-03905-x","DOIUrl":"10.1007/s12185-024-03905-x","url":null,"abstract":"We investigated the cost-effectiveness of treating iron deficiency anemia (IDA) with ferric citrate hydrate (FC) in Japan. We employed four treatment strategies: switching from sodium ferrous citrate (SF) to FC at (1) 500 mg (approximately 120 mg of iron) per day or (2) 1000 mg (approximately 240 mg of iron) per day in patients with SF-induced nausea/vomiting, or starting treatment with FC at (3) 500 mg/day or (4) 1000 mg/day. We evaluated the cost-effectiveness of these strategies compared with SF 100 mg (100 mg of iron) per day. Incremental effects over 26 weeks relative to SF 100 mg were 0.0052 quality-adjusted life years (QALYs) for (1) and (2), and 0.0044 QALYs for (3) and (4). From the payer's perspective, incremental cost-effectiveness ratios (ICERs: JPY/QALY) against SF 100 mg were: (1) 1,107,780, (2) 2,257,477, (3) 5,588,430, and (4) 11,544,816. All four FC strategies were dominant (less costly and more effective) from a limited societal perspective. Treatment with FC for IDA was cost-effective (ICER ≤ JPY 5,000,000/QALY) when switching strategies from the payer perspective, and cost-saving (all FC strategies) from limited societal perspectives. Individual patients' characteristics and cost-effectiveness should be considered in treatment selection.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"467-475"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjunctive effects of eltrombopag on immunosuppressive therapy for childhood aplastic anemia. 儿童再生障碍性贫血免疫抑制治疗中的辅助作用。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-04-01 Epub Date: 2024-12-27 DOI: 10.1007/s12185-024-03903-z

Katsuhide Eguchi, Masataka Ishimura, Shouichi Ohga, Saori Endo, Shoji Saito, Sachiyo Kamimura, Dai Keino, Shota Kato, Yoshihiro Azuma, Atsushi Watanabe, Akiko Inoue, Takeshi Higa, Shuichi Ozono, Naoto Fujita, Kenichiro Watanabe, Yoshiyuki Takahashi

{"title":"Adjunctive effects of eltrombopag on immunosuppressive therapy for childhood aplastic anemia.","authors":"Katsuhide Eguchi, Masataka Ishimura, Shouichi Ohga, Saori Endo, Shoji Saito, Sachiyo Kamimura, Dai Keino, Shota Kato, Yoshihiro Azuma, Atsushi Watanabe, Akiko Inoue, Takeshi Higa, Shuichi Ozono, Naoto Fujita, Kenichiro Watanabe, Yoshiyuki Takahashi","doi":"10.1007/s12185-024-03903-z","DOIUrl":"10.1007/s12185-024-03903-z","url":null,"abstract":"Eltrombopag is used with first-line immunosuppressive therapy for adult aplastic anemia, although its practical utility in childhood remains unclear. We retrospectively analyzed the outcomes of pediatric patients who received eltrombopag in Japan. Of the 27 eligible patients, 23 (85%) were previously treated, and 15 (56%) had severe or very-severe disease. Seventeen (63%) received eltrombopag with or after rabbit anti-thymocyte globulin plus cyclosporin-A. Within the first year of eltrombopag therapy, 12 patients showed a good or partial response, 15 showed no response, and 8 non-responders successfully underwent hematopoietic cell transplantation. Within the first 3 months after eltrombopag therapy, all but one of the transfusion-dependent responders became transfusion-independent. At 12 months, 6 of 12 responders were disease-free off-treatment. The one-year overall response rate was higher for severe or very-severe than non-severe cases (p = 0.006). Multivariable analysis showed that very-severe disease at the start of eltrombopag therapy was a predictor of being disease-free off-treatment (p = 0.03). No cytogenetic abnormalities developed, but myelofibrosis occurred 4 months after eltrombopag therapy in one non-responder with very-severe disease. The first 3 months' response to adjunctive eltrombopag may guide to the safe and effective use for the cure of disease, although prospective trials are needed to determine its long-term effects.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"533-542"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance. 移植后Ph+ ALL的tki：迄今为止的实践和临床意义。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-04-01 Epub Date: 2025-01-17 DOI: 10.1007/s12185-025-03917-1

Satoshi Nishiwaki, Seitaro Terakura, Takanobu Morishita, Tatsunori Goto, Yuichiro Inagaki, Kotaro Miyao, Nobuaki Fukushima, Daiki Hirano, Naoyuki Tange, Shingo Kurahashi, Yachiyo Kuwatsuka, Masanobu Kasai, Hiroatsu Iida, Kazutaka Ozeki, Masashi Sawa, Tetsuya Nishida, Hitoshi Kiyoi

{"title":"Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.","authors":"Satoshi Nishiwaki, Seitaro Terakura, Takanobu Morishita, Tatsunori Goto, Yuichiro Inagaki, Kotaro Miyao, Nobuaki Fukushima, Daiki Hirano, Naoyuki Tange, Shingo Kurahashi, Yachiyo Kuwatsuka, Masanobu Kasai, Hiroatsu Iida, Kazutaka Ozeki, Masashi Sawa, Tetsuya Nishida, Hitoshi Kiyoi","doi":"10.1007/s12185-025-03917-1","DOIUrl":"10.1007/s12185-025-03917-1","url":null,"abstract":"Post-transplant tyrosine kinase inhibitors (TKIs) show promise in preventing relapse after allogeneic hematopoietic cell transplantation (allo-HCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). However, their real-world use and efficacy remain unclear. A comprehensive study across seven centers included Ph+ALL patients who underwent allo-HCT between 2002 and 2022. Post-transplant TKIs were administered in 28% of patients (49 of 173 transplanted in complete remission): 7% as prophylaxis during complete molecular remission (CMR), and 21% in response to measurable residual disease (MRD) positivity. Median first post-transplant TKI duration was 13.7 months for the prophylactic group and 4.0 months for the MRD-triggered group. Prophylactic TKIs appear particularly beneficial for patients not in CMR at allo-HCT, showing a trend towards higher 5-year relapse-free survival (RFS) compared to those not receiving prophylactic TKIs (100% vs. 73%; P = 0.11). Significant RFS differences were observed between the prophylactic, non-TKI, and MRD-triggered groups. However, patients with white blood cell counts <15000/µl at diagnosis and no additional chromosomal abnormalities-an MRD-triggered high efficacy cluster-demonstrated comparable 5-year RFS regardless of TKI strategy (100% vs. 85% vs. 80%; P = 0.87). This cluster highlights the potential effectiveness of MRD-triggered TKI administration in select low-risk patients, suggesting tailored TKI strategies based on risk factors.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"494-503"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concomitant letermovir affects the optimal concentration-to-dose ratio of tacrolimus after switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving fluconazole prophylaxis. 在接受氟康唑预防的造血细胞移植患者中，他克莫司由静脉给药转为口服给药后，联用雷莫韦影响他克莫司的最佳浓度剂量比。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-04-01 Epub Date: 2025-02-10 DOI: 10.1007/s12185-025-03942-0

Toshihisa Nakashima, Yoshihiro Inamoto, Ayumu Ito, Sung-Won Kim, Takahiro Fukuda, Hironobu Hashimoto

{"title":"Concomitant letermovir affects the optimal concentration-to-dose ratio of tacrolimus after switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving fluconazole prophylaxis.","authors":"Toshihisa Nakashima, Yoshihiro Inamoto, Ayumu Ito, Sung-Won Kim, Takahiro Fukuda, Hironobu Hashimoto","doi":"10.1007/s12185-025-03942-0","DOIUrl":"10.1007/s12185-025-03942-0","url":null,"abstract":"Letermovir is often administered for cytomegalovirus prophylaxis after allogeneic hematopoietic cell transplantation (HCT). Concomitant use of letermovir and azole antifungals affects tacrolimus concentration. Therefore, in HCT recipients taking fluconazole, letermovir may affect the optimal tacrolimus conversion ratios when switching from continuous intravenous infusion to oral administration. In this study, we retrospectively evaluated tacrolimus conversion ratios in 104 HCT recipients taking fluconazole with and without concomitant letermovir. The median tacrolimus concentration-to-dose (C/D) ratios with and without letermovir were 18.2 and 20.6 (ng/mL)/(mg/day), respectively, before conversion from continuous infusion (C/Dciv) (p = 0.21) and 2.9 and 1.9 (ng/mL)/(mg/day), respectively, after conversion (p < 0.01). The median (C/Dpo)/(C/Dciv) ratios with and without letermovir were 0.15 and 0.10, respectively (p < 0.01). These results suggest that in HCT recipients taking fluconazole, the optimal conversion ratio when switching from continuous intravenous infusion to oral administration is 0.7-fold lower with concomitant letermovir than without it.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"462-466"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone. 接受达拉单抗、来那度胺和地塞米松治疗的新诊断多发性骨髓瘤患者不适合移植的带状疱疹发病率

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-31 DOI: 10.1007/s12185-025-03980-8

Yuichi Horigome, Hirotoshi Kamata, Yusuke Michishita, Maki Yokoyama, Noriyuki Tadera, Kei Hayama, Takahiro Suzuki

{"title":"Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone.","authors":"Yuichi Horigome, Hirotoshi Kamata, Yusuke Michishita, Maki Yokoyama, Noriyuki Tadera, Kei Hayama, Takahiro Suzuki","doi":"10.1007/s12185-025-03980-8","DOIUrl":"https://doi.org/10.1007/s12185-025-03980-8","url":null,"abstract":"Combination therapy with daratumumab, lenalidomide, and dexamethasone (D-Rd) has greatly improved outcomes for transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM). Effective management of herpes zoster (HZ) and other infections is critical to maximize therapeutic benefit and to maintain treatment continuity. However, antiviral prophylaxis for HZ in TIE-NDMM patients receiving D-Rd has unclear efficacy, and is currently not covered by health insurance in Japan. In this study, we retrospectively analyzed the incidence of HZ in 40 TIE-NDMM patients treated with D-Rd. Nine patients (22.5%) developed HZ at a median period of 10.7 months (range, 0.4-34.2 months) after starting D-Rd. The cumulative HZ incidence at 12, 24, and 36 months was 13.3%, 19.5%, and 28.6%, respectively. Development of HZ was not associated with patient characteristics, disease characteristics, or hematologic response. Our data indicate a high incidence of HZ in TIE-NDMM patients receiving D-Rd, and we anticipate that Japanese health insurance should soon cover prophylactic treatment of HZ in D-Rd.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia. pegaspargase在日本急性淋巴细胞白血病患者中的2期多中心研究。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-31 DOI: 10.1007/s12185-025-03976-4

Katsuyoshi Koh, Yoshiyuki Kosaka, Yasuhiro Okamoto, Naoko Maeda, Atsushi Ogawa, Ryoji Kobayashi, Daisuke Hasegawa, Nobuhiro Koga, Adrien Tessier, Yelena Shvenke, Jian Zhu, Bouchra Benettaib, Keizo Horibe, Chitose Ogawa

{"title":"Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia.","authors":"Katsuyoshi Koh, Yoshiyuki Kosaka, Yasuhiro Okamoto, Naoko Maeda, Atsushi Ogawa, Ryoji Kobayashi, Daisuke Hasegawa, Nobuhiro Koga, Adrien Tessier, Yelena Shvenke, Jian Zhu, Bouchra Benettaib, Keizo Horibe, Chitose Ogawa","doi":"10.1007/s12185-025-03976-4","DOIUrl":"https://doi.org/10.1007/s12185-025-03976-4","url":null,"abstract":"Pegaspargase is a pegylated formulation of E. coli-derived asparaginase, which when combined with multi-agent chemotherapy is an effective, well-established therapy for acute lymphoblastic leukemia (ALL). This study evaluated the efficacy, safety and pharmacokinetics of lyophilized pegaspargase in the Japanese population. The study had two parts; the primary endpoint for Part 1 was the incidence and nature of treatment-emergent adverse events (TEAEs), including those related to pegaspargase, to determine the number of patients who experience intolerable toxicity during a tolerability assessment period. The primary endpoint for Part 2 was the percentage of patients with plasma asparaginase activity of ≥ 0.1 IU/ml 14 days after administration of the first dose of lyophilized pegaspargase. All 26 patients included in the safety analysis experienced at least one TEAE. Frequently reported TEAEs related to lyophilized pegaspargase included decreases in blood fibrinogen, antithrombin III, white blood cell count, and platelet count. No deaths were reported. Plasma asparaginase activity reached ≥ 0.1 IU/ml 5 min after the first dose of lyophilized pegaspargase and was maintained for 14 days in all patients with evaluable samples. The results of this study show that lyophilized pegaspargase represents an effective and well-tolerated first-line treatment option in Japanese patients with ALL.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistent neonatal alloimmune thrombocytopenia caused by triple anti-HLA-A11, -B3901, and -Cw7 antibodies. 由hla - a11、-B3901和-Cw7三重抗体引起的持久性新生儿同种免疫血小板减少症。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-31 DOI: 10.1007/s12185-025-03968-4

Shiho Hatano, Hajime Maeda, Hirotaka Ichikawa, Kei Ogasawara, Nozomi Takano, Shunya Rikimaru, Kinuyo Kawabata, Kazuhiko Ikeda, Hitoshi Ohto, Hayato Go

{"title":"Persistent neonatal alloimmune thrombocytopenia caused by triple anti-HLA-A11, -B3901, and -Cw7 antibodies.","authors":"Shiho Hatano, Hajime Maeda, Hirotaka Ichikawa, Kei Ogasawara, Nozomi Takano, Shunya Rikimaru, Kinuyo Kawabata, Kazuhiko Ikeda, Hitoshi Ohto, Hayato Go","doi":"10.1007/s12185-025-03968-4","DOIUrl":"https://doi.org/10.1007/s12185-025-03968-4","url":null,"abstract":"Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is primarily caused by the transplacental passage of maternal antibodies commonly directed against fetal human platelet antigens (HPA) and rarely against human leukocyte antigens (HLA).Study design and methods: Here, we report a case of prolonged neonatal alloimmune thrombocytopenia (NAIT) associated with three anti-HLA antibodies. A male infant was delivered at 37 weeks' gestation because of non-reassuring fetal status. His platelet count decreased to 14 × 109/L on postnatal day 8. A random-donor platelet transfusion and intravenous immunoglobulin were administered without clinical complications. Immunoserological investigations were performed to identify HLA, HPA, and antibodies in the patient and his parents.Results: Anti-HLA-A11, -B3901, and -Cw7 antibodies, but not anti-HPA antibodies, were identified in the mother's blood that reacted with the lymphocytes of the infant and his father.Conclusion: Three distinct anti-HLA (HLA-A11, B3901, and Cw7) may have caused the prolonged neonatal thrombocytopenia observed in the present case. This case report demonstrates the role of anti-HLA antibodies in the pathogenesis of FNAIT.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction. 组织学确认和放射治疗有助于在有肿瘤耀斑反应的患者中继续使用依霉素单抗。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-29 DOI: 10.1007/s12185-025-03979-1

Mai Fujita, Sho Okamoto, Kazuki Jinnouchi, Keita Kai, Tatsuya Mihashi, Keisuke Kidoguchi, Kana Kusaba, Haruhiko Sano, Hidekazu Itamura, Mariko Yoshimura, Hiroo Katsuya, Toshihiko Ando, Shinya Kimura

引用次数: 0